NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

“You think THAT indicates a successful trial? Celldex and IMUC showed immune responses.(Iclight)”

I know…” the proof of the pudding is in the eating”.
But i believe that her words are well thought out! For me the quote of Linda Liau is very, very meaningful!

Quote:
“I have a huge drive to prove that things that seem impossible can actually work,” said Liau. “When I first started working on brain tumor immunotherapy, everyone told me that you can’t mount an immune response in the brain. Now we know that’s not true.”

dd: 9/28/2017 http://medschool.ucla.edu/body.cfm?id=1158&action=detail&ref=1165

And i like also this interview (june 2016):

What is the biggest lesson you gained from business school? The biggest lesson I gained from business school is the importance of personal relationships and teamwork. True leadership is much more about “we” than about “me”.

What achievement are you most proud of in your professional career? Developing the first cellular vaccine (DCVax) for brain cancer.

And this is from april 2016:
quote
“When brain-tumor researchers are asked about the most promising areas for future study, both genetic profiling and immunotherapy consistently top the list, Dr. Liau says. UCLA is at the forefront of both fields. UCLA’s immune-based therapies currently in clinical trials use treatments that enable the immune system to kill tumor cells by targeting factors, known as immune checkpoint inhibitors, which impede the immune system from successful tumor control. In addition, Dr. Liau and her colleagues developed the first dendritic cell (DC)-based vaccine, known as DCVax, for brain-tumor patients to be used in humans. “The problem with brain tumors is that, despite treatment, they tend to come back,” Dr. Liau says. “The promise of immunotherapy and vaccines is that they can hopefully prevent the cancer from returning.”

Fifteen years ago, most experts believed it was not possible, because of the blood-brain barrier, for patients to mount an immune response to brain cancers. “We’ve found that these tumor vaccines can not only mount an immune response, but that a significant percentage of patients have had no recurrence for more than 10 years now, which for glioblastoma is very rare,” Dr. Liau says.

Currently, Dr. Liau and her colleagues at the UCLA Brain Tumor Center have begun to publish on genetic profiling and biomarkers to determine which patients are likely to fare well on immunotherapy. “Right now, we’re treating everyone the same way,” she says. “I am hopeful that in the next few years, we will have biomarkers that we can test either in the patient’s blood or via imaging. With these biomarkers, we will know in advance which patients will respond, and for those who won’t, we will work on other ways to treat the tumor.”
https://connect.uclahealth.org/2016/04/26/multipronged-approach-takes-aim-at-malignant-brain-tumors/

Happy New Year!